This course has concluded on November 30, 2022

CE InformationCourse Outline

    Targeted Approaches in Multiple Myeloma: Emerging Therapies and Management Strategies

    FACULTY

    Kenneth C. Anderson, MD
    Kraft Family Professor of Medicine
    Director, Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    James R. Berenson, MD
    Medical Director
    Institute for Myeloma and Bone Cancer Research
    West Hollywood, California

    Faith E. Davies, MD
    Director Myeloma Clinal Program
    Perlmutter Cancer Center
    NYU Grossman School of Medicine
    New York, New York

    Adam D. Cohen, MD
    Associate Professor of Medicine
    Abramson Cancer Center
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Jonathan L. Kaufman, MD
    Professor of Hematology and Medical Oncology
    Winship Cancer Institute
    Emory University Medicine
    Atlanta, Georgia

    Sagar Lonial, MD, FACP
    Professor and Chair of Hematology and Medical Oncology
    Emory University Medicine
    Atlanta, Georgia

    Ruben Niesvizky, MD, FACP
    Professor of Medicine
    Director of Multiple Myeloma Center and of Oncology Operations
    Weill Cornell Medicine/ New York Presbyterian Hospital
    New York, New York

    PROVIDER STATEMENT

    Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Global Company.

    For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

    INTENDED LEARNERS

    This activity is designed for a national and international audience of hematologists; hematologic, medical, radiation, and surgical oncologists; hematopathologists; and other health care providers, including pathologists, oncology and health-system pharmacists, oncology nurses, nurse practitioners, physician assistants, residents/fellows, and other clinicians involved and/or interested in the therapeutic management of patients with hematologic malignancies.

    LEARNING OBJECTIVES

    After participating in this activity, learners should be better able to:

    • Define the current standard of care for R/R MM as reflected in evolving, new and emerging MM therapies
    • Evaluate the clinical efficacy and safety data surrounding new and emerging MM therapies
    • Identify MM management strategies that incorporate novel therapeutic targets to overcome barriers associated with therapeutic resistance, toxicities, and tolerability

    CLAIMING CREDIT

    To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

    Release Date: November 30, 2021 
    Expiration Date: November 30, 2022
    Estimated Time to Complete: 3.25 hours

    There is no fee associated with this activity.

    COMMERICAL SUPPORT

    The following companies have provided an educational grant in support of this activity: Karyopharm Therapeutics and Oncopeptides, Inc.

    CONTINUING EDUCATION

     

    In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    PHYSICIANS

    NACCME designates this internet enduring activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NURSES

    This continuing nursing education internet enduring activity awards 3.25 contact hours.

    Provider approved by the California Board of Registered Nursing, Provider #13255 for 3.25 contact hours. 

    NURSE PRACTITIONERS

    American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

    PHARMACISTS

    This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-9999-21-212-H01-P) has been approved for a maximum of 3.25 contact hours (.325 CEUs).

    The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

    PHYSICIAN ASSISTANTS

    NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet live/enduring activity is designated for 3.25 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

    USE OF PROPRIETARY NAMES

    This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

    DISCLAIMERS

    The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

    Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

    The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

    DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

    NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

    In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

    Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

    1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
    2. Any investigational, off-label, or non-FDA approved content or discussion

    NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

    Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

    1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
    2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
    3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

    FACULTY

    The faculty has reported the following:

    Kenneth C. Anderson: Advisory Board - C4 Therapeutics, Oncopep, Inc., Raqia; Consultant - Amgen, AstraZeneca, Janssen, Mana Therapeutics, Pfizer Inc, Precision Biosciences, Starton Therapeutics

    James R. Berenson: Advisory Board - Bristol Myers Squibb, Karyopharm, Oncopeptides, Sanofi; Consultant - Bristol Myers Squibb, Karyopharm, Oncopeptides, Sanofi; Grant/Research Support - Amgen, Bristol Myers Squibb, Karyopharm, Sanofi, Takeda/Millenium; Speakers Bureau - Amgen, Bristol Myers Squibb, Janssen, Karyopharm, Oncopeptides, Sanodi, Takeda/Millenium; Stockholder - ONCOtracker

    Adam D. Cohen: Advisory Board - AstraZeneca, Bristol Myers Squibb/Celgene, Genentech/Roche, GlaxoSmithKline, Janssen, Millennium/Takeda, Oncopeptides, Seattle Genetics; Consultant - Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen; Grant/Research Support - GlaxoSmithKline, Novartis; Other - Novartis

    Jonathan L. Kaufman: Grant/Research Support - AbbVie, Amgen, Bristol Myers Squibb, GlaxoSmithKline; Consultant - Incyte

    Ruben Niesvizky: Consultant - Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Sanofi Genzyme, AstraZeneca, BeiGene,Takeda, Targeted Oncology

    Sagar Lonial: Other - TG Therapeutics

    Alexander Keith Stewart: Consultant - GlaxoSmithKline, Oncopeptides, Inc., Ono Pharmaceuticals, Sanofi, Skyline Diagnostics, Tempus Health; Grant/Research Support - Amgen, Janssen

    PLANNING COMMITTEE

    Samantha Conforti, Kelly Jackson, Paul O'Neil, Amrita Kabi, and Greaton Sellers from NACCME and Imedex have disclosed no relevant financial relationships with any ineligible company (commercial interest).

    NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

    ADA STATEMENT

    North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

    PRIVACY POLICY

    NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

    Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

    GRIEVANCE POLICY

    Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers,  Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.